Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck

EEW Cohen, AB Halpern, K Kasza, M Kocherginsky… - Oral oncology, 2009 - Elsevier
Single agent epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) have
demonstrated reproducible response rates of 5–15% in treatment of squamous cell …
被引用次数：59 相关文章

Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck.

EE Cohen, AB Halpern, K Kasza, M Kocherginsky… - Oral …, 2009 - europepmc.org
Single agent epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) have
demonstrated reproducible response rates of 5–15% in treatment of squamous cell …

Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck

EEW Cohen, AB Halpern, K Kasza… - Oral …, 2009 - pubmed.ncbi.nlm.nih.gov
Single agent epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) have
demonstrated reproducible response rates of 5-15% in treatment of squamous cell …

Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck

EEW Cohen, AB Halpern, K Kasza… - Oral …, 2009 - scholars.northwestern.edu
Single agent epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) have
demonstrated reproducible response rates of 5-15% in treatment of squamous cell …
[HTML] nih.gov

[HTML][HTML] Factors Associated with Clinical Benefit from Epidermal Growth Factor Receptor Inhibitors in Recurrent and Metastatic Squamous Cell Carcinoma of the Head …

EEW Cohen, AB Halpern, K Kasza, M Kocherginsky… - Oral …, 2009 - ncbi.nlm.nih.gov
Single agent epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) have
demonstrated reproducible response rates of 5–15% in treatment of squamous cell …

Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck

EEW Cohen, AB Halpern, K Kasza, M Kocherginsky… - Oral Oncology, 2009 - infona.pl
Single agent epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) have
demonstrated reproducible response rates of 5–15% in treatment of squamous cell …